🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Esperion Therapeutics, Inc. Common Stock ESPR R2KPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.esperion.com
Company Profile ↓
$3.18
- 1Y
Mkt Cap$819.46M
P/B-2.56
52W High$3.18
52W Low$3.18
Book Value$-1.20

Company Overview

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. As of July 13, 2026, Esperion Therapeutics, Inc. was taken private.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 36.5%.

Steady Revenue Expansion

Revenue has grown at a 12.1% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $403.13M (+21.3% YoY); net profit $-22.68M.
  • Trailing 12 Months Year-on-year growth — revenue +23.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:12.12%
1 Year:23.20%

Stock Price Performance

1 Year:-
6 Months:-
3 Months:-
1 Month:-

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 36.5%.
  • Compounding revenue at 12.1% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-
Industry PE
25.17
Forward P/E
12.35
PEG Ratio
-
Book Value
$-1.20
Price to Book
-2.56
P/S
1.96
EV/EBITDA
15.89
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
12.12%
Profit 5Y
-
Revenue (YoY)
23.20%
Earnings (YoY)
-

Profitability & Returns

ROCE
36.51%
ROE
7.51%
ROA
12.04%
Profit Margin
-1.77%
Op Margin
-8.22%
Gross Margin
57.79%
EPS (Latest Qtr)
$-0.10
EPS (TTM)
$0.00

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.96
Current Ratio
1.53
Debt
$543.81M
Total Assets
$462.53M
Current Assets
$459.46M
Working Capital
$161.76M

Ownership

Promoter Holding
0.90%
Chg in Prom Hold
-
FII / Inst Holding
71.54%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$819.46M
Total Revenue (TTM)
$418.24M
EBITDA
$75.89M
Free Cash Flow
$-49.71M
Operating Cash Flow
$-18.19M
Shares Outstanding
257.69M
Gross Margin
57.79%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ESPR Esperion Therapeutics, Inc. Common Stock R2KPHARMA 3.18 - $819.46M 0.00% 36.51% 7.51% 12.12% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------------145.42M982.00K981.00K982.00K1.84M212.24M3.83M9.64M7.98M40.66M14.41M18.84M18.84M18.98M24.33M25.79M33.97M137.74M73.83M--65.00M82.39M87.31M168.45M80.10M
Cost of Revenue -----------------------------------31.54M28.54M41.29M27.85M34.57M
Gross Profit -----------------------------------33.46M53.84M46.02M140.59M45.53M
Operating Expenses -----------------------------------55.55M46.75M55.98M55.36M52.11M
Operating Income -12.92M-13.23M-14.82M-14.33M-17.71M-29.29M-40.89M-43.66M-45.74M-38.70M-46.89M-46.48M-50.56M-60.65M86.93M-55.30M-65.77M-58.96M-74.45M129.17M-80.55M-95.57M-82.82M-32.53M-55.74M-42.99M-52.38M-41.62M-48.60M-37.06M-27.53M72.27M2.58M---22.10M7.09M-9.96M85.23M-6.58M
EBITDA ------------------------------------21.00M7.79M-9.26M86.33M-5.37M
Interest Expense -----------------------------------19.43M20.49M22.05M22.64M19.80M
Pretax Income ------------------------------------40.45M-12.72M-31.33M63.67M-25.20M
Tax Provision ----------------------------------------
Net Income -12.80M-13.12M-14.59M-14.04M-17.40M-28.96M-40.54M-43.34M-45.22M-37.89M-46.13M-45.73M-49.91M-60.04M87.38M-54.22M-68.38M-61.95M-78.25M124.61M-85.44M-104.48M-90.94M-43.67M-69.39M-56.73M-66.32M-55.12M-61.72M-49.94M-41.25M61.02M-61.92M---40.45M-12.72M-31.33M61.83M-25.20M
Diluted EPS -----------1.73-1.71--3.07-2.01-2.52-2.26-2.844.32-3.07-3.89-3.50-1.67-2.62-0.93-1.05-0.81-0.79-0.46-0.370.34-0.33---0.21-0.02-0.160.22-0.10

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------0148.36M227.55M78.45M75.47M116.33M332.31M403.13M
Cost of Revenue -----------26.97M43.27M68.60M129.22M
Gross Profit -----------48.51M73.07M263.71M273.91M
Operating Expenses -----------228.01M228.63M209.31M213.64M
Operating Income -10.16M-10.20M-22.76M-36.22M-50.04M-76.15M-168.98M-204.59M-93.10M-121.40M-226.73M-179.50M-155.56M54.40M60.27M
EBITDA ------------176.35M-150.11M7.57M63.87M
Interest Expense -----------56.81M58.98M59.25M84.60M
Pretax Income ------------233.66M-209.25M-51.74M-20.84M
Tax Provision ------------001.84M
Net Income -10.82M-11.74M-26.09M-36.38M-49.78M-74.98M-166.99M-201.81M-97.17M-143.55M-269.11M-233.66M-209.25M-51.74M-22.68M
Diluted EPS ---------3.59-5.23-9.31-3.52-2.03-0.28-0.11

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --7.31M78.29M143.28M295.57M245.21M277.83M143.45M214.45M353.26M-247.94M205.80M343.82M465.89M
Current Assets ------------246.68M201.06M338.00M462.57M
Cash & Equivalents 3.41M1.57M6.51M56.54M85.04M77.34M38.16M34.47M36.97M166.13M304.96M-124.78M82.25M144.76M167.85M
Inventory ------------35.20M65.62M94.49M105.12M
Receivables ------------33.73M48.49M80.14M140.19M
Total Liabilities --24.70M4.20M9.72M8.31M16.61M33.14M64.33M194.50M449.39M-571.72M660.79M732.54M767.85M
Current Liabilities --17.17M4.20M5.49M5.62M15.59M33.14M64.33M66.08M94.07M-92.31M156.22M246.23M300.81M
Long Term Debt --7.53M-4.23M2.69M1.02M-----259.90M261.60M237.72M249.48M
Total Debt ------------260.95M266.17M297.60M252.23M
Total Equity -19.31M-30.03M-41.37M74.09M133.55M287.26M228.60M244.69M79.12M19.95M-96.13M--323.78M-454.99M-388.72M-301.96M
Shares Outstanding ------------76.56M120.20M197.85M247.21M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -----38.16M-47.73M-131.30M-148.64M-70.34M-85.18M-263.81M-174.83M-135.49M-23.65M-13.09M
Investing Cash Flow -----160.07M10.12M-35.85M140.45M64.23M21.36M-50.48M8.10M42.50M-317.00K0
Financing Cash Flow ----190.52M-1.56M163.46M10.69M136.19M201.72M268.22M32.61M50.46M86.48M36.18M
Capital Expenditure -33.63K-7.00K-31.00K-873.00K-325.00K-94.00K-19.00K-151.00K-953.00K-869.00K-0-0-0-317.00K-0
Free Cash Flow -----38.48M-47.82M-131.32M-148.79M-71.29M-86.05M-263.81M-174.83M-135.49M-23.97M-13.09M
Share Buybacks -------0055.00M0----

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------64.3%62.8%79.4%67.9%
Operating Margin % ---------62.8%-53.3%-289.0%-237.8%-133.7%16.4%15.0%
Net Margin % ---------65.5%-63.1%-343.0%-309.6%-179.9%-15.6%-5.6%
ROE % 36.0%28.4%-35.2%-27.2%-17.3%-32.8%-68.2%-255.1%-487.0%149.3%-72.2%46.0%13.3%7.5%
ROCE % -103.5%-30.7%-26.3%-17.3%-33.2%-69.1%-258.6%-62.8%-46.8%--115.3%-313.8%55.7%36.5%

Shareholding Pattern

Insiders
0.90%
Institutions
71.54%
Public Float
72.19%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 6.93% 17.85M $56.77M
2 Two Seas Capital Lp 4.42% 11.39M $36.24M
3 Orbimed Advisors LLC. 4.10% 10.57M $33.61M
4 Vanguard Capital Management LLC 4.05% 10.43M $33.18M
5 Two Sigma Investments, LP 3.67% 9.46M $30.08M
6 Marshall Wace LLP 2.75% 7.08M $22.50M
7 State Street Corporation 2.74% 7.06M $22.44M
8 Shaw D.E. & Co., Inc. 2.54% 6.54M $20.80M
9 Geode Capital Management, LLC 2.31% 5.96M $18.94M
10 AIGH Capital Management LLC 1.71% 4.40M $13.99M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ESPR

Google News Mon, 07 Sep 2026

ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOaVJjMll2RlBORG1lQUd3SFlmMkFyQl9RQTF3TEZ2SjdkREZYUVBwVnA4WkI3cGxlQzk4cTA2LU81UnpGZFlfN1FMOG9hLU5TTW9CZmF2bEpPSmtrbjNxcWp4NFNvekxpY3g4eUxWNHRTQXdxdjR3UWd5WFY1S3BuT0p6MmxCUXdzUzhkOU…

Google News Mon, 22 Jun 2026

Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPejBxandLS2JaaV9WTjNmWTVIZVBRYkE4eS1FMEpISnhocVlnMEpFVFBGazFRMjhYY0lHOHNQNUtfMWNkd3p0RS1VMnVaVEkwM2Q1YVpKbnc4c2xvLTN3MmphVS1ERGdFbXBma1A2ZDl6OTJzTExvemM3RU80al8wZE9xVV9ielp2djkyQ0…

Google News Fri, 10 Jul 2026

ESPR Stock Price, Quote & Chart - ChartMill

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ycXpGWlM5dmE0OGVFbmN0c1oxYlMtbVI5WHZxQk5mcGY2SnRSZDR3eHdudm5yQmFPbkVuQjdUZ08zMjdsQ0VreGIwd0Q2cVQ1R09kUGlVS2VCZXQtbE5R?oc=5" target="_blank">ESPR Stock Price, Quote & Chart</a>&nbs…

Google News Fri, 01 May 2026

ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire

<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxNTGQyUHlXVS10TUpfazk5SEhfRzRjMXRBaG1LMmw1bWFCV0dRdDc0b25MWFNxWGVEVV9QREppQjdGOGNfUEFmX20zRmhHNWpyM3NPM284WDI3YUM4ODN5UTZUNGxVMUMxYzUyU2o5Vmotalk2MWRfYXFuWTNCaDQzaVNHakRIZU1ZNjE1Yn…

Google News ue, 07 Apr 2026

$ESPR stock is down 10% today. Here's what we see in our data. - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPSmxQRUpGYnNTNTdjNWUwek5hSHl5RmVBSjAtSjRWZ0Jnem8yTXRFcm9vSzh1cndzQWVjSkxxLXpQLTlJMlk4OWtnZzJsZ1d0TVdUQVRoMXRzZ05rcXZINC1zaEJsVzAta0xOV1FKTmJmNFEtVXNKa1M1eUFjUnNMSUNENXVod2Jjemh1bW…

Google News Sat, 16 May 2026

Epilogue On Esperion Therapeutics Stock (NASDAQ:ESPR) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9yU3FRQVh1elBaZ0puRkNsbm5NdWtuVS1rQWN5TFRndlJ0LXNPVmhwMU03YUtLRFIweFhiS01lcTdxdDNHQzFPc2pLM2lwZXhKT0hFcHc4NG8zV0VqVmtndUtXbmNMc2tDVTRFTFJjM3JEYml2YnFCS0VvZ2VBR1U?oc=5" target="_bla…

ESPR — Frequently Asked Questions

What is the current share price of Esperion Therapeutics, Inc. Common Stock (ESPR)?

As of 2026-09-07 16:24 PDT, Esperion Therapeutics, Inc. Common Stock (ESPR) trades at $3.18 on NasdaqGM. Its 52-week range is $3.18 to $3.18.

What is the market capitalisation of ESPR?

Esperion Therapeutics, Inc. Common Stock (ESPR) has a market capitalisation of $819.46M on NasdaqGM.

What is the return on equity (ROE) of ESPR?

ESPR has a return on equity (ROE) of 7.51%. Its return on capital employed (ROCE) is 36.51%.

Is ESPR a good stock to buy?

This page provides a data-driven analysis of Esperion Therapeutics, Inc. Common Stock (ESPR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space